New drugs and perspectives for new anti-tuberculosis regimens
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease. With growing drug resistance the epidemic remains and will require significant attention and investment for the elimination of this disease to occur. With susceptible TB treatment not changing over the last...
Main Authors: | S. Tiberi, M. Muñoz-Torrico, R. Duarte, M. Dalcolmo, L. D’Ambrosio, G.-B. Migliori |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier España
2018-03-01
|
Series: | Pulmonology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2173511517301690 |
Similar Items
-
New anti-tuberculosis drugs and regimens: 2015 update
by: Lia D'Ambrosio, et al.
Published: (2015-05-01) -
Classifying new anti-tuberculosis drugs: rationale and future perspectives
by: Simon Tiberi, et al.
Published: (2017-03-01) -
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis
by: Denise Rossato Silva, et al. -
Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs
by: Simon Tiberi, et al.
Published: (2019-03-01) -
Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings
by: Giovanni Sotgiu, et al.
Published: (2017-03-01)